|
1
|
Mohanty R, Chowdhury CR, Arega S, Sen P,
Ganguly P and Ganguly N: CAR T cell therapy: A new era for cancer
treatment (Review). Oncol Rep. 42:2183–2195. 2019.PubMed/NCBI
|
|
2
|
Ma CC, Wang ZL, Xu T, He ZY and Wie YQ:
The approved gene therapy drugs worldwide: From 1998 to 2019.
Biotechnol Adv. 40:1075022020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schubert ML, Hückelhoven A, Hoffmann JM,
Schmitt A, Wuchter P, Sellner L, Hofmann S, Ho AD, Dreger P and
Schmitt M: Chimeric antigen receptor T cell therapy targeting
CD19-positive leukemia and lymphoma in the context of stem cell
transplantation. Hum Gene Ther. 27:758–771. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sadelain M, Riviere I and Riddell S:
Therapeutic T cell engineering. Nature. 545:423–431. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
June CH and Sadelain M: Chimeric antigen
receptor therapy. N Engl J Med. 379:64–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maude SL, Laetsch TW, Buechner J, Rives S,
Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers
GD, et al: Tisagenlecleucel in children and young adults with
B-cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davila ML, Riviere I, Wang X, Bartido S,
Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska
M, et al: Efficacy and toxicity management of 19-28z CAR T cell
therapy in B cell acute lymphoblastic leukemia. Sci Transl Med.
6:224ra2252014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park JH, Riviere I, Gonen M, Wang X,
Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et
al: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic
leukemia. N Engl J Med. 378:449–459. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Porter DL, Hwang WT, Frey NV, Lacey SF,
Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al:
Chimeric antigen receptor T cells persist and induce sustained
remissions in relapsed refractory chronic lymphocytic leukemia. Sci
Transl Med. 7:303ra1392015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Turtle CJ, Hay KA, Hanafi LA, Li D,
Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, et al:
Durable molecular remissions in chronic lymphocytic leukemia
treated with CD19-specific chimeric antigen receptor-modified T
cells after failure of ibrutinib. J Clin Oncol. 35:3010–3020. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schuster SJ, Svoboda J, Chong EA, Nasta
SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V,
Landsburg D, et al: Chimeric antigen receptor T cells in refractory
B-cell lymphomas. N Engl J Med. 377:2545–2554. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Neelapu SS, Locke FL, Bartlett NL, Lekakis
LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T,
Lin Y, et al: Axicabtagene ciloleucel CAR T-cell therapy in
refractory large B-cell lymphoma. N Engl J Med. 377:2531–2544.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grupp S, Hu ZH, Zhang Y, Keating A,
Pulsipher MA, Philips C, Margossian SP, Rosenthal J, Salzberg D,
Schiff DE, et al: Tisagenlecleucel Chimeric Antigen Receptor (CAR)
T-Cell Therapy for Relapsed/Refractory Children and young adults
with Acute Lymphoblastic Leukemia (ALL): Real World Experience from
the Center for International Blood and Marrow Transplant Research
(CIBMTR) and Cellular Therapy (CT) Registry. Blood. 134:26192019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jaglowski S, Hu ZH, Zhang Y, Kamdar M,
Ghosh M, Lulla P, Sasine J, Perales MA, Hematti P, Nikiforow S, et
al: Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy
for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World
Experience from the Center for International Blood & Marrow
Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood.
134:7662019. View Article : Google Scholar
|
|
15
|
Nastoupil LJ, Jain MD, Feng L, Spiegel JY,
Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, et al:
Standard-of-Care Axicabtagene Ciloleucel for relapsed or refractory
large B-cell lymphoma: Results From the US Lymphoma CAR T
consortium. J Clin Oncol. 38:3119–3128. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang M, Munoz J, Goy A, Locke FL, Jacobson
CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, et al:
KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell
lymphoma. N Engl J Med. 382:1331–1342. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sotillo E, Barrett DM, Black KL, Bagashev
A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, et
al: Convergence of acquired mutations and alternative splicing of
CD19 enables resistance to CART-19 immunotherapy. Cancer Discov.
5:1282–1295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fischer J, Paret C, El Malki K, Alt F,
Wingerter A, Neu MA, Kron B, Russo A, Lehmann N, Roth L, et al:
CD19 isoforms enabling resistance to CART-19 immunotherapy are
expressed in B-ALL patients at initial diagnosis. J Immunother.
40:187–195. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee DW, Kochenderfer JN, Stetler-Stevenson
M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M,
Shah NN, et al: T cells expressing CD19 chimeric antigen receptors
for acute lymphoblastic leukaemia in children and young adults: A
phase 1 dose-escalation trial. Lancet. 385:517–528. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shah NN and Fry TJ: Mechanisms of
resistance to CAR T cell therapy. Nat Rev Clin Oncol. 16:372–385.
2019.PubMed/NCBI
|
|
21
|
Cook A, Bono F, Jinek M and Conti E:
Structural biology of nucleocytoplasmic transport. Annu Rev
Biochem. 76:647–671. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen
P, Sun YJ, Tang LN and Zheng SE: The expression of CRM1 is
associated with prognosis in human osteosarcoma. Oncol Rep.
21:229–235. 2009.PubMed/NCBI
|
|
23
|
van der Watt PJ, Zemanay W, Govender D,
Hendricks DT, Parker MI and Leaner VD: Elevated expression of the
nuclear export protein, CRM1 (exportin 1), associates with human
oesophageal squamous cell carcinoma. Oncol Rep. 32:730–738. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Noske A, Weichert W, Niesporek S, Roske A,
Buckendahl AC, Koch I, Sehouli J, Dietel M and Denkert C:
Expression of the nuclear export protein chromosomal region
maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian
cancer. Cancer. 112:1733–1743. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen A, Wang Y, Zhao Y, Zou L, Sun L and
Cheng C: Expression of CRM1 in human gliomas and its significance
in p27 expression and clinical prognosis. Neurosurgery. 65:153–160.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van der Watt PJ, Maske CP, Hendricks DT,
Parker MI, Denny L, Govender D, Birrer MJ and Leaner VD: The
Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed
in cervical cancer and are critical for cancer cell survival and
proliferation. Int J Cancer. 124:1829–1840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tai YT, Landesman Y, Acharya C, Calle Y,
Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, et
al: CRM1 inhibition induces tumor cell cytotoxicity and impairs
osteoclastogenesis in multiple myeloma: Molecular mechanisms and
therapeutic implications. Leukemia. 28:155–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kojima K, Kornblau SM, Ruvolo V, Dilip A,
Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, et al:
Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
Blood. 121:4166–4174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo B, Huang L, Gu Y, Li C, Lu H, Chen G,
Peng Z and Feng Z: Expression of exportin-1 in diffuse large B-cell
lymphoma: Immunohistochemistry and TCGA analyses. Int J Clin Exp
Pathol. 11:5547–5560. 2018.PubMed/NCBI
|
|
30
|
Lapalombella R, Sun Q, Williams K,
Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta
S, et al: Selective inhibitors of nuclear export show that
CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood.
120:4621–4634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang K, Wang M, Tamayo AT, Shacham S,
Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, et al: Novel
selective inhibitors of nuclear export CRM1 antagonists for therapy
in mantle cell lymphoma. Exp Hematol. 41:67–78.e4. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bahlis NJ, Sutherland H, White D, Sebag M,
Lentzsch S, Kotb R, Venner CP, Gasparetto C, Del Col A, Neri P, et
al: Selinexor plus low-dose bortezomib and dexamethasone for
patients with relapsed or refractory multiple myeloma. Blood.
132:2546–2554. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vercruysse T, De Bie J, Neggers JE,
Jacquemyn M, Vanstreels E, Schmid-Burgk JL, Hornung V, Baloglu E,
Landesman Y, Senapedis W, et al: The second-generation exportin-1
inhibitor KPT-8602 demonstrates potent activity against acute
lymphoblastic leukemia. Clin Cancer Res. 23:2528–2541. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ming M, Wu W, Xie B, Sukhanova M, Wang W,
Kadri S, Sharma S, Lee J, Shacham S, Landesman Y, et al: XPO1
inhibitor selinexor overcomes intrinsic ibrutinib resistance in
mantle cell lymphoma via nuclear retention of IκB. Mol Cancer Ther.
17:2564–2574. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kuruvilla J, Savona M, Baz R, Mau-Sorensen
PM, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, et
al: Selective inhibition of nuclear export with selinexor in
patients with non-Hodgkin lymphoma. Blood. 129:3175–3183. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gravina GL, Senapedis W, McCauley D,
Baloglu E, Shacham S and Festuccia C: Nucleo-cytoplasmic transport
as a therapeutic target of cancer. J Hematol Oncol. 7:852014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chari A, Vogl DT, Gavriatopoulou M, Nooka
AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, et al:
Oral selinexor-dexamethasone for triple-class refractory multiple
myeloma. N Engl J Med. 381:727–738. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Machlus KR, Wu SK, Vijey P, Soussou TS,
Liu ZJ, Shacham E, Unger TJ, Kashyap T, Klebanov B, Sola-Visner M,
et al: Selinexor-induced thrombocytopenia results from inhibition
of thrombopoietin signaling in early megakaryopoiesis. Blood.
130:1132–1143. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Etchin J, Berezovskaya A, Conway AS,
Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y,
Kauffman M, Shacham S, et al: KPT-8602, a second-generation
inhibitor of XPO1-mediated nuclear export, is well tolerated and
highly active against AML blasts and leukemia-initiating cells.
Leukemia. 31:143–150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schubert ML, Schmitt A, Sellner L, Neuber
B, Kunz J, Wuchter P, Kunz A, Gern U, Michels B, Hofmann S, et al:
Treatment of patients with relapsed or refractory CD19+ lymphoid
disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta
retroviral vector: A unicentre phase I/II clinical trial protocol.
BMJ Open. 9:e0266442019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hoffmann JM, Schubert ML, Wang L,
Huckelhoven A, Sellner L, Stock S, Schmitt A, Kleist C, Gern U,
Loskog A, et al: Differences in expansion potential of naive
chimeric antigen receptor T cells from healthy donors and untreated
chronic lymphocytic leukemia patients. Front Immunol. 8:19562018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stock S, Ubelhart R, Schubert ML, Fan F,
He B, Hoffmann JM, Wang L, Wang S, Gong W, Neuber B, et al:
Idelalisib for optimized CD19-specific chimeric antigen receptor T
cells in chronic lymphocytic leukemia patients. Int J Cancer.
145:1312–1324. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yoo HJ, Liu Y, Wang L, Schubert ML,
Hoffmann JM, Wang S, Neuber B, Huckelhoven-Krauss A, Gern U,
Schmitt A, et al: Tumor-specific reactive oxygen species
accelerators improve chimeric antigen receptor t cell therapy in B
cell malignancies. Int J Mol Sci. 20:24692019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang L, Gong W, Wang S, Neuber B, Sellner
L, Schubert ML, Huckelhoven-Krauss A, Kunz A, Gern U, Michels B, et
al: Improvement of in vitro potency assays by a resting step for
clinical-grade chimeric antigen receptor engineered T cells.
Cytotherapy. 21:566–578. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Armitage JO, Gascoyne RD, Lunning MA and
Cavalli F: Non-hodgkin lymphoma. Lancet. 390:298–310. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Riches JC, Davies JK, McClanahan F, Fatah
R, Iqbal S, Agrawal S, Ramsay AG and Gribben JG: T cells from CLL
patients exhibit features of T-cell exhaustion but retain capacity
for cytokine production. Blood. 121:1612–1621. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schubert ML, Hoffmann JM, Dreger P,
Muller-Tidow C and Schmitt M: Chimeric antigen receptor transduced
T cells: Tuning up for the next generation. Int J Cancer.
142:1738–1747. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gargett T, Yu W, Dotti G, Yvon ES, Christo
SN, Hayball JD, Lewis ID, Brenner MK and Brown MP: GD2-specific CAR
T cells undergo potent activation and deletion following antigen
encounter but can be protected from activation-induced cell death
by PD-1 blockade. Mol Ther. 24:1135–1149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cao Y, Lu W, Sun R, Jin X, Cheng L, He X,
Wang L, Yuan T, Lyu C and Zhao M: Anti-CD19 chimeric antigen
receptor T cells in combination with nivolumab are safe and
effective against relapsed/refractory B-cell Non-Hodgkin lymphoma.
Front Oncol. 9:7672019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fraietta JA, Beckwith KA, Patel PR, Ruella
M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE,
Cook DR, et al: Ibrutinib enhances chimeric antigen receptor T-cell
engraftment and efficacy in leukemia. Blood. 127:1117–1127. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ruella M, Kenderian SS, Shestova O,
Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH and Gill
S: Kinase inhibitor ibrutinib to prevent cytokine-release syndrome
after anti-cd19 chimeric antigen receptor t cells for b-cell
neoplasms. Leukemia. 31:246–248. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gauthier J, Hirayama AV, Purushe J, Hay
KA, Lymp J, Li DH, Yeung CCS, Sheih A, Pender BS, Hawkins RM, et
al: Feasibility and efficacy of CD19-targeted CAR-T cells with
concurrent ibrutinib for CLL after ibrutinib failure. Blood.
135:1650–1660. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tan DS, Bedard PL, Kuruvilla J, Siu LL and
Razak AR: Promising SINEs for embargoing nuclear-cytoplasmic export
as an anticancer strategy. Cancer Discov. 4:527–537. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hing ZA, Fung HY, Ranganathan P, Mitchell
S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, et
al: Next-generation XPO1 inhibitor shows improved efficacy and in
vivo tolerability in hematological malignancies. Leukemia.
30:2364–2372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu D, Grishin NV and Chook YM: Nesdb: A
database of NES-containing CRM1 cargoes. Mol Biol Cell.
23:3673–3676. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tyler PM, Servos MM, de Vries RC, Klebanov
B, Kashyap T, Sacham S, Landesman Y, Dougan M and Dougan SK:
Clinical dosing regimen of selinexor maintains normal immune
homeostasis and T-cell effector function in mice: Implications for
combination with immunotherapy. Mol Cancer Ther. 16:428–439. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bhattacharya S and Schindler C: Regulation
of STAT3 nuclear export. J Clin Invest. 111:553–559. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fraietta JA, Lacey SF, Orlando EJ,
Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y,
O'Connor RS, Hwang WT, et al: Determinants of response and
resistance to CD19 chimeric antigen receptor (CAR) T cell therapy
of chronic lymphocytic leukemia. Nat Med. 24:563–571. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kagoya Y, Tanaka S, Guo T, Anczurowski M,
Wang CH, Saso K, Butler MO, Minden MD and Hirano N: A novel
chimeric antigen receptor containing a JAK-STAT signaling domain
mediates superior antitumor effects. Nat Med. 24:352–359. 2018.
View Article : Google Scholar : PubMed/NCBI
|
